1'-[4-(2,4-dioxo-1,3-thiazolidin-5-yl)benzyl]-2'-oxo-1',4'-dihydro-2'H-spiro[cyclopropane-1,3'-quinoline]-7'-carboxylic acid | 928142-77-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1'-[4-(2,4-dioxo-1,3-thiazolidin-5-yl)benzyl]-2'-oxo-1',4'-dihydro-2'H-spiro[cyclopropane-1,3'-quinoline]-7'-carboxylic acid
• 英文别名: 1-[[4-(2,4-dioxo-1,3-thiazolidin-5-yl)phenyl]methyl]-2-oxospiro[4H-quinoline-3,1'-cyclopropane]-7-carboxylic acid
• CAS: 928142-77-2
• 化学式: C₂₂H₁₈N₂O₅S
• 分子量: 422.461
• InChiKey: RIYPOVNONGDPLS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  129
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Detection and Treatment of Schizophrenia
  申请人：Itokawa Masanari

  公开号：US20110028470A1

  公开（公告）日：2011-02-03

  The present invention provides a method for diagnosing schizophrenia, and a schizophrenia diagnostic reagent or device for use in the method. The present invention further provides a therapeutic or ameliorating agent for schizophrenia, which is effective for the treatment or amelioration of schizophrenia. The therapeutic or ameliorating agent for schizophrenia contains a carbonyl scavenger or a carbonyl-modified protein formation inhibitor as an active ingredient. The method for diagnosing schizophrenia according to the present invention includes measuring at least one parameter in a subject, the parameter being selected from the group consisting of: (1) a genetic abnormality of glyoxalase I gene; (2) the expression level or activity of glyoxalase I in a biological sample; (3) the amount of a carbonyl compound or a carbonyl-modified protein that is a protein modified with the carbonyl compound; and (4) the amount of pyridoxal in a biological sample.

  本发明提供了一种用于诊断精神分裂症的方法，以及用于该方法的精神分裂症诊断试剂或设备。本发明进一步提供了一种治疗或改善精神分裂症的药剂，该药剂对于治疗或改善精神分裂症有效。用于治疗或改善精神分裂症的药剂包含醛固定剂或醛修饰蛋白形成抑制剂作为活性成分。根据本发明的诊断精神分裂症的方法包括在受试者中测量至少一个参数，所述参数选自以下组合：（1）甘氧化酶I基因的遗传异常；（2）生物样本中甘氧化酶I的表达水平或活性；（3）蛋白质中醛化合物或经醛化合物修饰的蛋白质的量；以及（4）生物样本中吡哆醛的量。
• DETECTION AND TREATMENT OF SCHIZOPHRENIA
  申请人：TOKAI UNIVERSITY EDUCATIONAL SYSTEM

  公开号：EP2189537A1

  公开（公告）日：2010-05-26

  The present invention provides a method for diagnosing schizophrenia, and a schizophrenia diagnostic reagent or device for use in the method. The present invention further provides a therapeutic or ameliorating agent for schizophrenia, which is effective for the treatment or amelioration of schizophrenia. The therapeutic or ameliorating agent for schizophrenia contains a carbonyl scavenger or a carbonyl-modified protein formation inhibitor as an active ingredient. The method for diagnosing schizophrenia according to the present invention includes measuring at least one parameter in a subject, the parameter being selected from the group consisting of: (1) a genetic abnormality of glyoxalase I gene; (2) the expression level or activity of glyoxalase I in a biological sample; (3) the amount of a carbonyl compound or a carbonyl-modified protein that is a protein modified with the carbonyl compound; and (4) the amount of pyridoxal in a biological sample.

  本发明提供了一种诊断精神分裂症的方法，以及一种用于该方法的精神分裂症诊断试剂或装置。本发明进一步提供了一种治疗或改善精神分裂症的药剂，该药剂可有效治疗或改善精神分裂症。精神分裂症的治疗剂或改善剂含有羰基清除剂或羰基修饰蛋白形成抑制剂作为活性成分。根据本发明的诊断精神分裂症的方法包括测量受试者体内的至少一个参数，该参数选自由以下组成的组：(1)乙二醛酶I基因的遗传异常；(2)生物样本中乙二醛酶I的表达水平或活性；(3)羰基化合物或羰基修饰蛋白的量，该蛋白是用羰基化合物修饰的蛋白；(4)生物样本中吡哆醛的量。
• Detection and treatment of schizophrenia
  申请人：TOKAI UNIVERSITY EDUCATIONAL SYSTEM

  公开号：EP2662453A2

  公开（公告）日：2013-11-13

  The present invention relates to a method for diagnosing schizophrenia comprising measuring at least one parameter in a subject, the parameter being selected from the group consisting of (1) a genetic abnormality of glyoxalase I gene, (2) the expression level or activity of glyoxalase I in a biological sample, (3) the amount of a carbonyl-modified protein that is a protein modified with the carbonyl-compound, preferably pentosidine, in a biological sample, and (4) the amount of pyridoxal in a biological sample. The present further relates to a primer, a probe and a reagent for use in said method, as well as an AGE-reader and its use for measuring the amount of carbonyl-modified proteins.

  本发明涉及一种诊断精神分裂症的方法，该方法包括测量受试者体内的至少一个参数，该参数选自以下组别：(1)乙二醛酶 I 基因的遗传异常；(2)生物样本中乙二醛酶 I 的表达水平或活性；(3)生物样本中羰基修饰蛋白质的量，该蛋白质是用羰基化合物（最好是喷托西啶）修饰的蛋白质；(4)生物样本中吡哆醛的量。本发明还涉及一种用于上述方法的引物、探针和试剂，以及一种 AGE 读取器及其在测量羰基修饰蛋白质量时的用途。
• US8809329B2
  申请人：——

  公开号：US8809329B2

  公开（公告）日：2014-08-19